ArticleClinical and experimental immunology2011

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.

G Sinnathamby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.